Showing results (21-30 of 79) with videos related to
Sort By:
Pageof 8
Molecular Pharmaceutics|February 14, 2013
A single mutant, A276S of p53, turns the switch to apoptosisShams Reaz, Mohanad Mossalam, Abood Okal, et al.Therapeutic Delivery|November 16, 2013
Basics and recent advances in peptide and protein drug deliveryBenjamin J Bruno, Geoffrey D Miller, Carol S LimBiologics : Targets & Therapy|October 29, 2014
Resistant mutations in CML and Ph(+)ALL - role of ponatinibGeoffrey D Miller, Benjamin J Bruno, Carol S LimJournal of Ovarian Research|May 2, 2019
Narrowing the field: cancer-specific promoters for mitochondrially-targeted p53-BH3 fusion gene therapy in ovarian cancerKatherine Redd Bowman, Ji Hoon Kim, Carol S LimJournal of Controlled Release : Official Journal of the Controlled Release Society|October 21, 2015
Delivery of drugs and macromolecules to the mitochondria for cancer therapyPhong Lu, Benjamin J Bruno, Malena Rabenau, et al.Molecular Pharmaceutics|August 24, 2013
The DNA binding domain of p53 is sufficient to trigger a potent apoptotic response at the mitochondriaKarina J Matissek, Mohanad Mossalam, Abood Okal, et al.Pharmaceutical Research|March 18, 2014
Delivery of a monomeric p53 subdomain with mitochondrial targeting signals from pro-apoptotic Bak or BaxKarina J Matissek, Abood Okal, Mohanad Mossalam, et al.Biomolecules|January 21, 2023
The Challenges and Prospects of p53-Based Therapies in Ovarian CancerBryce Wallis, Katherine Redd Bowman, Phong Lu, et al.Plos One|January 24, 2013
Solid phase synthesis of mitochondrial triphenylphosphonium-vitamin E metabolite using a lysine linker for reversal of oxidative stressMohanad Mossalam, Jamie Soto, Carol S Lim, et al.Pharmaceutical Research|November 19, 2003
Correlation among agonist dose, rate of import, and transcriptional activity of liganded progesterone receptor B isoform in living cellsHenan Li, Guang Yan, Steven E Kern, et al.Pageof 8